Drug updated on 4/16/2024

Dosage FormTablet (oral; 45 mg)
Drug ClassNeurokinin 3 (NK3) receptor antagonists
Ongoing and
Completed Studies


  • Indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Fezolinetant (Veozah) is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. It has been found effective in reducing symptom frequency and improving quality of life, including sleep quality.
  • The information about fezolinetant was derived from three systematic reviews/meta-analyses.
  • Compared with hormone therapy (HT) and non-hormonal therapies for treating postmenopausal vasomotor symptoms, fezolinetant significantly reduced the frequency of these symptoms more than all evaluated non-HTs but didn't differ significantly on frequency reduction compared to HT regimens.
  • In a meta-analysis involving 2,168 participants across five studies, it was highlighted that fezolinetant notably improved sleep quality in postmenopausal women experiencing moderate to severe VMS. This improvement also reflected positively on the Menopause-Specific Quality of Life measure, indicating its beneficial effect beyond just symptom reduction.
  • As part of the neurokinin 1 and 3 receptor antagonists group, which are known for limiting the severity of hot flashes in menopausal women, fezolinetant emerged as a promising option for those seeking non-hormonal treatments for VMS. However, further clinical trials were suggested before solidifying efficacy conclusions regarding this drug class.
  • All studies specifically targeted postmenopausal women experiencing moderate-to-severe vasomotor symptoms, emphasizing the meaningful impact of Veozah within this population. However, certain HT regimens might offer superior results, suggesting personalized treatment decisions based on effectiveness, safety, availability, and consideration of long-term use, especially among specific subgroups with pre-existing conditions, given the lack of extensive safety data comparison.